Autres langues Acrux Limited

Actions

ACR

AU000000ACR3

Produits pharmaceutiques

Marché Fermé - Australian S.E. 03:46:52 25/08/2026			Varia. 5j.	Varia. 1 janv.
0,0100 ^AUD	+11,11%		+11,11%	-33,33%

24/08	Acrux Limited annonce la nomination de Jolanta Airey au poste de directrice médicale	CI
17/08	Transcript : Acrux Limited - Special Call

Autres langues

24/08	Acrux Limited Announces Appointment of Jolanta Airey as Chief Medical Officer
28/05	Acrux licenses Lenzetto for Australian market for A$5.4 million
27/05	Hungary's Richter and Acrux agree to license transdermal estradiol spray for Australia
27/05	Gedeon Richter Plc. and Acrux Limited Extend License Agreement for Lenzetto® in Australia
14/05	Acrux says capital gains tax exemptions remain in place for Acrux
11/05	Acrux raises A$1.6 mln via at 0.95 au cents per share
07/05	Acrux requests trading halt
24/02	Acrux Limited Reports Earnings Results for the Half Year Ended December 31, 2025
29/08/25	Acrux Limited Reports Earnings Results for the Full Year Ended June 30, 2025
29/08/25	Acrux Ltd posts FY loss attributable of A$5.9 million
28/08/25	Acrux Limited Auditor Raises 'Going Concern' Doubt
31/07/25	Acrux Signs 10-Year Licensing Deal For Dapsone Gel in Saudi Arabia
31/07/25	Acrux signs agreement with Servacure for Dapsone gel in Saudi Arabia
09/05/25	ASX Small-Cap Stocks to Watch
07/05/25	Acrux Appoints John Warmbrun as CEO
07/05/25	Acrux Ltd Appoints John Warmbrunn As CEO And Managing Director
28/03/25	ASX Biggest Losers
25/02/25	Acrux Limited Reports Earnings Results for the Half Year Ended December 31, 2024
07/02/25	Acrux Ltd Says CEO Michael Kotsanis Announced Retirement
07/02/25	Acrux CEO to Retire
16/01/25	Acrux Launches 90-Gram Version of Dapsone 5% Gel in US
29/08/24	Acrux Limited Reports Earnings Results for the Full Year Ended June 30, 2024
28/08/24	Acrux Limited Auditor Raises 'Going Concern' Doubt
27/08/24	Acrux Secures US FDA Approval for Generic Version of Acne Medication; Shares Jump 15%
28/06/24	Acrux Secures AU$1.5 Million Funding Facility; Shares Fall 3%